MedPath

Tramadol

Generic Name
Tramadol
Brand Names
Conzip, Durela, Qdolo, Ralivia, Ryzolt, Seglentis, Tridural, Ultracet, Ultram, Zytram
Drug Type
Small Molecule
Chemical Formula
C16H25NO2
CAS Number
27203-92-5
Unique Ingredient Identifier
39J1LGJ30J

Overview

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Background

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Indication

Tramadol is approved for the management of moderate to severe pain in adults. Tramadol is also used off-label in the treatment of premature ejaculation.

Associated Conditions

  • Acute Pain
  • Premature Ejaculation
  • Severe Pain
  • Acute, moderate, severe Pain
  • Moderate Pain

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/06/29
Not Applicable
Completed
Syed Muhammad Abbas
2025/02/05
N/A
Recruiting
2024/12/19
Phase 4
Active, not recruiting
medina medical center
2024/12/11
Not Applicable
Not yet recruiting
2024/12/09
Phase 3
Recruiting
2024/09/25
Phase 4
Not yet recruiting
2024/09/19
Phase 4
Completed
Istanbul University - Cerrahpasa (IUC)
2024/08/20
Early Phase 1
ENROLLING_BY_INVITATION
2024/04/26
Phase 2
Completed
Asbjørn Mohr Drewes
2024/04/18
Phase 4
Recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Aidarex Pharmaceuticals LLC
33261-483
ORAL
50 mg in 1 1
10/5/2012
Aidarex Pharmaceuticals LLC
33261-105
ORAL
50 mg in 1 1
10/22/2014
NuCare Pharmaceuticals,Inc.
68071-2648
ORAL
100 mg in 1 1
2/25/2022
Medsource Pharmaceuticals
45865-357
ORAL
50 mg in 1 1
7/19/2015
Medsource Pharmaceuticals
45865-170
ORAL
37.5 mg in 1 1
3/5/2024
Lupin Pharmaceuticals, Inc.
68180-697
ORAL
100 mg in 1 1
1/16/2024
Galephar Pharmaceutical Research Inc.
66277-239
ORAL
100 mg in 1 1
12/19/2022
Quality Care Products, LLC
55700-996
ORAL
100 mg in 1 1
2/24/2023
Sun Pharmaceutical Industries, Inc.
47335-860
ORAL
200 mg in 1 1
12/12/2023
Palmetto Pharmaceuticals, Inc.
68134-402
ORAL
5 mg in 1 mL
12/21/2023

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
SKUDEXA FILM-COATED TABLET 75 MG/25 MG
SIN15394P
TABLET, FILM COATED
75 mg
12/13/2017
PENGESIC CAPSULE 50 mg
SIN10512P
CAPSULE
50.00 mg
12/8/1998
ACUGESIC INJECTION 50 mg/ml (without preservative)
SIN10045P
INJECTION
50 mg/ml
9/23/1998
MABRON INJECTION 100 mg/2 ml
SIN08740P
INJECTION
100 mg/2 ml
6/6/1996
ULTRADOL F.C. TABLETS 37.5MG/325MG
SIN16498P
TABLET, FILM COATED
37.5mg
5/19/2022
TRADOL INJECTION 50 mg/ml
SIN10057P
INJECTION
50 mg/ml
9/23/1998
ACUGESIC CAPSULE 50 mg
SIN08953P
CAPSULE
50 mg
10/2/1996
TRAMADOL STADA INJECTION 100 mg/2 ml
SIN08367P
INJECTION
100 mg/2 ml
10/2/1995
TRACIDOL INJECTION 100mg/2ml
SIN15303P
INJECTION, SOLUTION
100mg
7/24/2017
TRAMADOL 50 STADA CAPSULE 50 mg
SIN08365P
CAPSULE
50 mg
10/2/1995

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Tramadol Hydrochloride Capsules
欧洲塞浦路斯麦道甘美大药厂
H20140362
化学药品
胶囊剂
11/5/2019
Tramadol Hydrochloride Capsules
国药准字H10950223
化学药品
胶囊剂
6/4/2020
Tramadol Hydrochloride Capsules
国药准字HJ20160417
化学药品
胶囊剂
7/5/2021
Tramadol Hydrochloride Capsules
medochemie ltd.
国药准字HJ20140362
化学药品
胶囊剂
4/15/2025
Tramadol Hydrochloride Suppositories
国药准字H20000738
化学药品
栓剂
6/17/2020
Tramadol Hydrochloride Injection
国药准字HJ20140813
化学药品
注射剂
8/20/2024
Tramadol Hydrochloride Injection
国药准字HJ20140812
化学药品
注射剂
8/20/2024
Tramadol Hydrochloride Injection
国药准字H20023537
化学药品
注射剂
7/23/2020
Tramadol Hydrochloride Injection
国药准字H10960107
化学药品
注射剂
3/15/2024
Tramadol Hydrochloride Injection
国药准字H10910037
化学药品
注射剂
9/23/2020
© Copyright 2025. All Rights Reserved by MedPath